Earning Analysis
Welcome to our in-depth analysis of Adaptive Biotechnologies Corp(ADPT) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Adaptive Biotechnologies Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-05 | After Hours | -0.16 | -0.15 | +6.25 | 64.65M | 93.97M | +45.36 | -11.54 | -17.40 |
| FY2025Q2 | 2025-08-05 | After Hours | -0.24 | -0.17 | +29.17 | 49.40M | 58.88M | +19.20 | +5.79 | +9.95 |
| FY2025Q1 | 2025-05-01 | After Hours | -0.28 | -0.20 | +28.57 | 42.13M | 52.44M | +24.49 | +33.70 | +19.70 |
| FY2024Q4 | 2025-02-11 | After Hours | -0.26 | -0.23 | +11.54 | 46.05M | 47.46M | +3.06 | -3.21 | +7.31 |
| FY2024Q2 | 2024-08-01 | - | -0.32 | -0.26 | +18.75 | 39.39M | 43.19M | +9.65 | -2.20 | -7.91 |
| FY2024Q1 | 2024-05-07 | - | -0.35 | -0.33 | +5.71 | 38.78M | 41.87M | +7.98 | -3.42 | +18.01 |
| FY2023Q4 | 2024-02-14 | - | -0.32 | -0.30 | +6.25 | 48.46M | 45.78M | -5.53 | +8.84 | +5.52 |
| FY2023Q3 | 2023-11-09 | - | -0.32 | -0.35 | -9.38 | 42.96M | 37.92M | -11.74 | -4.88 | -5.10 |
| - | 2023-05-03 | - | -0.34 | -0.40 | -17.65 | - | - | - | +6.99 | - |
| - | 2023-02-14 | - | -0.37 | -0.28 | +24.32 | - | - | - | -0.12 | +1.27 |
ADPT Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Adaptive Biotechnologies Corp reported performance for FY2025Q3, announced on 2025-11-05. The company achieved an EPS of -0.15, compared to analyst estimates of -0.16 by 6.25% . Revenue for the quarter reached 93.97M compared to expectations of 64.65M by 45.36% .
The stock price reacted with a -11.54% one-day change and a -17.40% five-day change following the earnings release. These movements reflect market reaction in Adaptive Biotechnologies Corp growth trajectory and strategic initiatives.
ADPT Earnings Forecast
Looking ahead, Adaptive Biotechnologies Corp(ADPT) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 59.28M and an EPS of -0.18.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 13.62%, while EPS estimates have been Revise Downward by -32.54%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -5.03% . These revisions correlate with a 35.88% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Adaptive Biotechnologies Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between ADPT's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+13.62%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-32.54%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-5.03%
In Past 3 Month
Stock Price
Go Up
+35.88%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:264.63M
--
EPS Estimate-Annual FY 2025:-0.49
—
Stock Price17.46
ADPT Revenue and EPS Performance: A Historical Perspective
Adaptive Biotechnologies Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-05,After Hours):
EPS: -0.15 (Actual) vs.-0.16 (Estimate) (6.25%)
Revenue: 93.97M (Actual) vs. 64.65M (Estimate) (45.36%)
Price Reaction: -11.54%(1-Day), -17.40%(5-Day)
FY2025Q2 (2025-08-05,After Hours):
EPS: -0.17 (Actual) vs.-0.24 (Estimate) (29.17%)
Revenue: 58.88M (Actual) vs. 49.40M (Estimate) (19.20%)
Price Reaction: 5.79%(1-Day), 9.95%(5-Day)
FY2025Q1 (2025-05-01,After Hours):
EPS: -0.20 (Actual) vs.-0.28 (Estimate) (28.57%)
Revenue: 52.44M (Actual) vs. 42.13M (Estimate) (24.49%)
Price Reaction: 33.70%(1-Day), 19.70%(5-Day)
Earnings Reaction
The chart below shows how ADPT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ADPT sees a -1.40% change in stock price 10 days leading up to the earnings, and a +3.42% change 10 days following the report. On the earnings day itself, the stock moves by +1.20%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -11.54% on the day following the earnings release and then changed by -13.87% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Summary
Positive
2025-11-06
The earnings call summary and Q&A section reveal several positive aspects: raised revenue guidance, improved margins, and strong growth in MRD volumes. The company's strategic partnerships and regulatory advancements, along with a clear path to profitability, are positive indicators. Despite some vague management responses, the overall sentiment is optimistic. The stock is likely to see a positive movement, with increased MRD revenue and improved cash burn guidance contributing to investor confidence.
Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Summary
Positive
2025-08-05
The earnings call highlights strong MRD revenue growth, positive adjusted EBITDA, and raised guidance, alongside strategic initiatives like EMR integrations and collaborations. The Q&A session reinforces the positive outlook with sustained volume growth and international expansion opportunities. Despite some management ambiguity, the overall sentiment is optimistic, driven by strong financial performance and strategic partnerships.
Adaptive Biotechnologies Corp (ADPT) Q1 2025 Earnings Call Summary
Positive
2025-05-01
The earnings call highlights significant revenue growth, improved margins, and reduced losses, which are positive indicators. The Q&A reveals strong growth in specific indications and EMR integrations, although some management responses lack clarity. The lowered spending guidance is a positive sign of cost control. Despite a net loss, the improved cash position and strategic partnerships like NeoGenomics suggest optimism. The overall sentiment is positive, with potential stock price appreciation in the short term.
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Summary
Positive
2024-11-08
The earnings call shows strong MRD revenue growth, reduced cash burn, and improved margins, which are positive indicators. Despite a decline in immune medicine revenue, the overall financial performance is robust. The Q&A provides confidence in future ASP increases and operational efficiencies, although management's unclear responses on guidance and cost reductions slightly temper enthusiasm. The increased MRD revenue guidance and reduced operating spend guidance are positive factors. The absence of a market cap suggests a smaller company, implying a stronger stock price reaction, leading to a positive prediction of 2% to 8%.
Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Summary
Positive
2024-08-02
The earnings call summary indicates strong financial performance with a 36% revenue increase, improved margins, and reduced operating expenses. MRD revenue grew significantly, and guidance for MRD revenue and cash burn was improved. Despite some uncertainties in FDA timing, the Q&A session revealed optimism about future growth and efficiency improvements. The positive financial metrics and optimistic outlook suggest a positive stock price movement in the short term.
People Also Watch
FAQ
What were the key highlights of ADPT’s latest earnings report for FY2025Q3?
How did ADPT’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for ADPT for 2025/Q4?
How does ADPT’s stock price correlate with earnings forecast revisions?
What should investors expect from ADPT’s next earnings report?